Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dragonfly Therapeutics
National Institutes of Health Clinical Center (CC)
Roswell Park Cancer Institute
Eli Lilly and Company
Dana-Farber Cancer Institute
PMV Pharmaceuticals, Inc
NeoImmuneTech
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Genmab
Tizona Therapeutics, Inc
BioInvent International AB
Essen Biotech
Ohio State University Comprehensive Cancer Center
IDEAYA Biosciences
Eli Lilly and Company
Seagen Inc.
Novartis
Obstetrics & Gynecology Hospital of Fudan University
Sotio Biotech Inc.
BicycleTx Limited
Merck Sharp & Dohme LLC
Maastricht University Medical Center
Merck Sharp & Dohme LLC
Eli Lilly and Company
University Health Network, Toronto
University of Washington
Mural Oncology, Inc
Merck Sharp & Dohme LLC
Toray Industries, Inc
OncoC4, Inc.
Mayo Clinic
Compugen Ltd
Roswell Park Cancer Institute
Sotio Biotech Inc.
Carisma Therapeutics Inc
NextCure, Inc.
ARCAGY/ GINECO GROUP
Five Prime Therapeutics, Inc.
Sellas Life Sciences Group
Eli Lilly and Company
Astellas Pharma Inc
Gustave Roussy, Cancer Campus, Grand Paris
NGM Biopharmaceuticals, Inc
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
NGM Biopharmaceuticals, Inc
ENB Therapeutics, Inc
National Cancer Institute (NCI)